logo-loader
viewTissue Regenix Group PLC

Tissue Regenix launches new unit as it inks US distribution deal

The changes will see the company focus on the surgical sector where its DermaPure product is gaining traction

surgeons working
The company has seen significant uptake in the orthopaedic trauma and urogynaecology segments

Tissue Regenix Group PLC (LON:TRX) shares popped higher on Monday morning after the firm announced the launch of a new business unit as well as unveiling an exclusive distribution deal for its flagship product.

Around 10.15am, Tissue Regenix shares were up 1.6% at 7.88p. 

The wound care specialist has set up TRX BioSurgery to further promote its DermaPure graft as surgical application following success in this sphere and the growing adoption of the product.

It has seen significant uptake in the orthopaedic trauma and urogynaecology segments.

Natural evolution

“Progressing from traditional wound care clinical settings to surgical applications is a natural evolution for DermaPure, which has proven to be clinically efficient in just a single application,” said said chief executive Steve Couldwell.

The Tissue Regenix boss also announced the formation of a distribution partnership with ARMS Medical.

Multi-year deal

The multi-year agreement gives ARMS exclusive rights to distribute DermaPure to hospitals and surgeons throughout the US for use in urology and gynecology procedures.

The partnership will allow the UK firm’s direct sales force to maintain their focus on soft tissue regeneration in the wound, plastics, orthopaedics and general surgery markets.

“Our partnership with ARMS Medical, who are known for bringing innovation to women's pelvic health solutions, allows us to leverage their strong relationships with key opinion leaders in the urogynaecology space to further access this market, whilst also maintaining commercial focus in our other key areas," Couldwell.

 -- Adds share price --

Quick facts: Tissue Regenix Group PLC

Price: 0.575 GBX

AIM:TRX
Market: AIM
Market Cap: £6.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

on 19/12/19

2 min read